Literature DB >> 16644782

Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

M Cutolo1, C M Montecucco, L Cavagna, R Caporali, S Capellino, P Montagna, L Fazzuoli, B Villaggio, B Seriolo, A Sulli.   

Abstract

BACKGROUND: Polymyalgia rheumatica (PMR) may create some difficulties in the differential diagnosis of elderly-onset rheumatoid arthritis (EORA) and of EORA with PMR-like onset (EORA/PMR). AIM: To investigate possible differences between three groups of patients, with regard to serum levels of inflammatory cytokines and steroidal hormones at baseline and after 1 month of treatment with glucocorticoids (prednisone 7.5-12.5 mg/day). PATIENTS AND METHODS: 14 patients with PMR, 15 with EORA and 14 with EORA/PMR, as well as 15 healthy, matched controls were analysed. Tumour necrosis factor alpha (TNFalpha), interleukin (IL)6, IL1 receptor antagonist (IL1Ra), cortisol, dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxy-progesterone (PRG) were evaluated.
RESULTS: Serum levels of both TNFalpha and IL6 were significantly higher in all three groups of patients than in controls (p<0.01). Serum IL6 levels were significantly higher in patients with both PMR and EORA/PMR than in patients with EORA (p<0.05). IL1Ra serum levels were significantly higher in patients with EORA than in controls (p<0.001) and in patients with PMR and EORA/PMR (p<0.05). DHEAS was significantly lower in patients with EORA/PMR than in those with EORA (p<0.05). PRG was significantly higher in all patient groups (p<0.05). After glucocorticoid treatment, serum TNFalpha and IL6 levels significantly decreased in all patient groups; IL1Ra significantly increased in patients with PMR and in those with EORA/PMR; cortisol, DHEAS, and PRG significantly decreased in patients with PMR and in those with EORA/PMR (p<0.05).
CONCLUSIONS: Different cytokine and steroidal hormone patterns suggest that patients with PMR and those with EORA/PMR seem to be have a more intensive inflammatory reaction and are more efficient responders to glucocorticoid treatment than patients with EORA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644782      PMCID: PMC1798362          DOI: 10.1136/ard.2006.051979

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  39 in total

Review 1.  Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease.

Authors:  M Cutolo; R H Straub
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

2.  Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment.

Authors:  I Watt; M Cobby
Journal:  Semin Arthritis Rheum       Date:  2001-04       Impact factor: 5.532

3.  Interleukin-1 cluster and tumor necrosis factor-alpha gene polymorphisms in polymyalgia rheumatica.

Authors:  L Boiardi; C Salvarani; J M Timms; T Silvestri; P L Macchioni; F S di Giovine
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

Review 4.  The hypothalamic-pituitary-adrenal and gonadal axes in rheumatoid arthritis.

Authors:  M Cutolo; B Villaggio; L Foppiani; M Briata; A Sulli; C Pizzorni; F Faelli; C Prete; L Felli; B Seriolo; M Giusti
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity.

Authors:  C Salvarani; B Casali; L Boiardi; A Ranzi; P Macchioni; D Nicoli; E Farnetti; M Brini; I Portioli
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

6.  Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.

Authors:  Maurizio Cutolo; Rainer H Straub; Luca Foppiani; Camilla Prete; Lia Pulsatelli; Alberto Sulli; Luigi Boiardi; Pierluigi Macchioni; Massimo Giusti; Carmen Pizzorni; Bruno Seriolo; Carlo Salvarani
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

7.  The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica.

Authors:  R H Straub; T Glück; M Cutolo; J Georgi; K Helmke; J Schölmerich; P Vaith; B Lang
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

8.  Elderly onset rheumatoid arthritis: clinical aspects.

Authors:  G Bajocchi; R La Corte; A Locaputo; M Govoni; F Trotta
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

9.  Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis.

Authors:  J Narváez; J M Nolla-Solé; J A Narváez; M T Clavaguera; J Valverde-García; D Roig-Escofet
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

10.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.

Authors:  R Caporali; C Montecucco; O Epis; F Bobbio-Pallavicini; T Maio; M A Cimmino
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

View more
  15 in total

Review 1.  Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature.

Authors:  Nádia Emi Aikawa; Rosa Maria Rodrigues Pereira; Laís Lage; Eloisa Bonfá; Jozélio Freire Carvalho
Journal:  Clin Rheumatol       Date:  2012-01-11       Impact factor: 2.980

Review 2.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

Review 3.  Glucocorticoids in rheumatoid arthritis.

Authors:  Roberto Caporali; Monica Todoerti; Garifallia Sakellariou; Carlomaurizio Montecucco
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 4.  Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.

Authors:  Beáta J Radovits; Wietske Kievit; Roland F J M Laan
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Patient demographics and disease variables correlate with distinct cytokine patterns in mitogen-stimulated peripheral blood mononuclear cells from rheumatoid arthritis patients.

Authors:  Sukhbir Singh Uppal; Raj Raghupathy; Sawsan J Hayat; Rafiqul Islam Chowdhury; Mini Abraham; Parvez Rawoot
Journal:  Rheumatol Int       Date:  2007-11-29       Impact factor: 2.631

6.  Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies.

Authors:  Elizabeth W Karlson; Lori B Chibnik; Shelley S Tworoger; I-Min Lee; Julie E Buring; Nancy A Shadick; Joann E Manson; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-03

7.  Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment.

Authors:  Frederik Flindt Kreiner; Henrik Galbo
Journal:  Arthritis Res Ther       Date:  2012-08-15       Impact factor: 5.156

8.  Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.

Authors:  Frederik Kreiner; Henrik Galbo
Journal:  Arthritis Res Ther       Date:  2010-09-20       Impact factor: 5.156

9.  Successful treatment with clarithromycin for patients with polymyalgia rheumatica.

Authors:  Masashi Ohe; Toshiyuki Bohgaki
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

10.  Clinical use of biologics in vasculitis syndromes.

Authors:  Marino Paroli
Journal:  Biologics       Date:  2012-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.